Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11555MR)

This product GTTS-WQ11555MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11555MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8414MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ970MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ15598MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ11154MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ7551MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ8774MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ12891MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW